Proteome Sciences plc (PMSNF)
Proteome Sciences plc operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Cobham, SU, GB. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $5.8M. On trailing twelve-month figures it carries a trailing P/E of -1.92, a net margin of -81.5%. Its beta of 0.15 implies it has historically moved less than the broad market.
Proteome Sciences Plc is a provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development. The company focuses on developing proprietary protein biomarkers for neurological diseases, oncology, and organ transplant rejection. Proteome Sciences was founded on December 10, 1993 and is headquartered in Cobham, the United Kingdom.
Proteome Sciences plc is most often compared with the following Healthcare names: